Table 1 Characteristics of the study population.
Demographic characteristics | Nā=ā67 |
---|---|
Age, years | 69ā±ā8 |
Female, n(%) | 29 (43) |
Cardiovascular Risk Factors | |
Family history of CAD, n(%) | 23 (34) |
Family history of stroke, n(%) | 8 (12) |
Systemic arterial hypertension, n(%) | 51 (76) |
Resistant hypertension, n(%) | 12 (18) |
Hypercholesterolemia, n(%) | 47 (70) |
Type 2 diabetes mellitus, n(%) | 16 (24) |
Current smoker, n(%) | 13 (20) |
Previous smoker, n(%) | 29 (43) |
Body mass index (kg/cm2) | 25ā±ā4 |
Framingham risk score (%) | 13 (6ā20) |
High cardiovascular risk n(%) | 36 (54) |
Cardiovascular History | |
Previous acute coronary syndrome, n(%) | 7 (10) |
Clinical Characteristics | |
Heart rate, bpm | 73 (67ā80) |
Systolic blood pressure, mmHg | 130 (125ā145) |
Diastolic blood pressure, mmHg | 80 (70ā80) |
Laboratory Parameters | |
White blood cells, 109/L | 7.4ā±ā1.7 |
Haemoglobin, g/dL | 14 (13ā15) |
Platelets, 109/L | 205 (163ā254) |
Total cholesterol, mg/dL | 175 (157ā198) |
LDL cholesterol, mg/dL | 105ā±ā33 |
HDL cholesterol, mg/dL | 43 (38ā50) |
Triglyceridemia, mg/dL | 129 (96ā162) |
Glycemia, mg/dL | 99 (88ā127) |
Creatinine, mg/dL | 0.85 (0.72ā1.04) |
eGFR, mL/min | 72 (58ā95) |
Medical Therapy | |
ACE inhibitors/ARBs, n(%) | 41 (61) |
β-blockers, n(%) | 27 (40) |
Calcium antagonists, n(%) | 18 (27) |
Diuretics, n (%) | 15 (22) |
Others vasodilators, n(%) | 4 (6) |
Number of anti-hypertensive agents | 1 (0ā2) |
Statins, n(%) | 40 (60) |
Antiplatelet agent, n(%) | 41 (61) |